We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

By LabMedica International staff writers
Posted on 01 May 2024
Print article
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow for the immediate and remote access to digital images of tissue samples, moving away from traditional physical glass slides that require microscope examination. The COVID-19 pandemic underscored the importance and utility of remote capabilities in pathology, significantly accelerating the adoption of digital pathology in the U.S. and boosting its market growth internationally.

Now, Sectra’s (Linköping, Sweden) digital pathology solution, along with Leica Biosystems’ (Nussloch, Germany) Aperio GT 450 DX, has received a 510(k) clearance by the US Food & Drug Administration (FDA). This marks the first FDA clearance within digital pathology that allows DICOM images to be used for pathology diagnostics and is a significant step towards standardization in this field. The Aperio GT 450, previously available under enforcement discretion due to the pandemic, is a well-established technology that delivers high-quality images at a fast turnaround time of less than 32 seconds per slide.

Leica Biosystems is not new to the regulated system market; the company boasts 25 years of experience in the digital pathology sector, where it has been integral in implementing, integrating, and innovating technologies that enhance cancer diagnosis and patient care. Sectra’s digital pathology solution is part of its broader enterprise imaging solution, designed to support a comprehensive approach to all imaging needs while reducing operational costs. This scalable and modular solution, centered around a versatile vendor-neutral archive (VNA), enables healthcare providers to grow from ology to ology and from enterprise to enterprise.

"There is no better time for laboratories to optimize their workflow with digital," said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. "Today, clinicians are faced with having to do more with less – digital pathology enables them to maintain a high standard of quality with world class images and a fast turnaround time, for the best patient care possible."

"Sectra has a strong track record of promoting and enabling open integrations and of pushing the development towards standardization within medical imaging IT. The recent FDA clearance including the clearance to utilize DICOM images for pathology diagnostics therefore makes me very proud,” said Dr. Torbjörn Kronander, CEO and President Sectra AB. “Due to the unique nature of the images used in digital pathology, proprietary formats have previously dominated. This FDA approval, including DICOM, shows that standardization is possible also within pathology. This is an important first step to a reality where healthcare providers can start reaping the benefits of a larger degree of freedom in choosing what hardware and software to combine, within pathology. This has the potential to increase workflow efficiency, facilitate the adoption of new technology and in the end—benefit patient care."

 

New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
LH ELISA
Luteinizing Hormone ELISA
New
Quantitative Immunoassay Analyzer
AS050

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Genome sequencing technology has the potential to detect thousands of genetic disease (Photo courtesy of 123RF)

Gene Technology Outperforms Standard Newborn Screening Tests in Pioneering Study

Since its introduction in the 1960s, newborn screening has grown to encompass dozens of primarily genetic disorders. The standard approach to newborn screening involves detecting specific biomarkers in... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.